// App-Quantinova.ai

: First-line pembrolizumab (pembro) monotherapy for advanced non-clear cell renal cell carcinoma (nccRCC): Results from KEYNOTE-427 cohort B.

Researchers

Presenter

  • David F. McDermott

Principal Investigators

  • Jae-Lyun Lee

  • Marek Ziobro

  • Rustem Airatovich Gafanov

  • Vsevolod Borisovich Matveev

  • Cristina Surez

  • Frede Donskov

  • Frederic Pouliot

  • Boris Y. Alekseev

  • Pawel Wiechno

  • Piotr Tomczak

  • Miguel Angel Climent Duran

  • Sang Joon Shin

  • Rachel Kloss Silverman

  • Rodolfo F. Perini

  • Charles Schloss

  • Michael B. Atkins

Medical Centers

  • Beth Israel Deaconess Medical Center, Boston, MA

  • Surgery, , Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of

  • Centrum Onkologii-Instytut im. Marii Sklodowskiej, Cracow, Poland

  • Russian Research Centre of Roentgenoradiology, Moscow, Russia

  • N. N. Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, Russia

  • Hospital Universitario del Mar, Barcelona, Spain

  • Aarhus University Hospital, Aarhus, Denmark

  • CHU de Quebec and Laval University, Quebec, QC, Canada

  • P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russian Federation

  • Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland

  • Clinical Hospital No. 1 of the Poznan University of Medical Sciences, Poznan, Poland

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Korea University College of Medicine, Seoul, Republic of Korea

  • Merck & Co., Inc., Kenilworth, NJ

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

Locations

  • United States

  • Poland

  • Russia

  • Spain

  • Denmark

  • Canada

  • Republic of South Korea

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Metastatic Renal Cell Cancer

  • Solid malignancies

  • non-clear cell renal carcinoma

Biomarkers

  • Programmed death-ligand 1

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Multinational

  • Cohort

Phase

  • NA

Study Id's

  • NCT02853344

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved